Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells*

We employed cDNA microarrays to identify the differentially expressed genes in a cisplatin-sensitive parental (2008) human ovarian carcinoma cell line and its cisplatin-resistant variant (2008/C13*). Differential expression of five genes was found in the 2008/C13* cells, a result confirmed by semi-quantitative reverse transcription-PCR. The five genes were identified as fibroblast muscle-type tropomyosin and skeletal muscle-type tropomyosin, dihydrodiol dehydrogenase, apolipoprotein J and glucose-6-phosphate dehydrogenase variant-A. Treatment of the 2008 cells with cisplatin (at its IC50 concentration of 2 μm) induced expression of these genes, as determined by semi-quantitative reverse transcription-PCR analysis using gene-specific primers. In contrast, treatment of the drug-resistant 2008/C13* cells with cisplatin (at its IC50 concentration of 20 μm) did not lead to the induction of any of the aforementioned genes. Most importantly, constitutive overexpression of dihydrodiol dehydrogenase (but not the other genes) in the 2008 cells led to induction of cisplatin resistance, clearly indicating its role in the development of the resistance phenotype in the 2008/C13* cells. The development of cisplatin resistance in the transfected cells was associated with an increase in the dihydrodiol dehydrogenase enzyme activity. Although at present it is not clear how dihydrodiol dehydrogenase is involved in cisplatin resistance, the identification of this gene as a causal factor suggests the existence of a hitherto undefined pathway resulting in cisplatin resistance.

• Publication year

  2002

• Venue

  Journal of Biological Chemistry

• Publication date

  2002-04-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/jbc.M112028200PMID 11842089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors

  2009cited by this paper
• Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells

  2009cited by this paper
• Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells

  2004cited by this paper
• Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.

  2001cited by this paper
• Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

  2001cited by this paper
• c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells.

  2001cited by this paper
• Increased expression of peroxiredoxin II confers resistance to cisplatin.

  2001cited by this paper
• Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.

  2000cited by this paper
• Influence of the proto-oncogene c-fos on cisplatin sensitivity.

  2000cited by this paper
• Cisplatin resistance and oncogenes - a review

  2000cited by this paper
• Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray.

  2000cited by this paper
• Identification of genes differentially expressed in association with acquired cisplatin resistance

  2000cited by this paper
• Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.

  2000cited by this paper
• Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells.

  2000cited by this paper
• A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.

  2000cited by this paper
• Suppression of src-induced transformed phenotype by expression of tropomyosin-1

  1999cited by this paper
• Effects of G6PD overexpression in NIH3T3 cells treated with tert-butyl hydroperoxide or paraquat.

  1998cited by this paper
• Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer

  1998cited by this paper
• The role of DNA mismatch repair in drug resistance.

  1998cited by this paper
• Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells.

  1998cited by this paper
• Tropomyosin isoforms in nonmuscle cells.

  1997cited by this paper
• Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

  1997cited by this paper
• Two differentially expressed genes in normal human prostate tissue and in carcinoma.

  1996cited by this paper
• Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver.

  1995cited by this paper
• The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity.

  1995cited by this paper
• Clusterin: physiologic and pathophysiologic considerations.

  1995cited by this paper
• G6PD deficiency.

  1994cited by this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cited by this paper
• Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics.

  1994cited by this paper
• Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells.

  1993cited by this paper
• In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

  1993cited by this paper
• Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.

  1992cited by this paper
• Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

  1992cited by this paper
• Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

  1992cited by this paper
• Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

  1992cited by this paper
• Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

  1992cited by this paper
• Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.

  1992cited by this paper
• Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.

  1991cited by this paper
• Modulation of cis‐diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3‐isobutyl‐1‐methylxanthine in sensitive and resistant human ovarian carcinoma cells

  1991cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.

  1988cited by this paper
• Enhanced DNA repair and resistance to cisplatin in human ovarian cancer.

  1988cited by this paper
• Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

  1985cited by this paper
• Drugs five years later. Cisplatin.

  1984cited by this paper

• AKR1C inhibitors medroxyprogesterone acetate and mefenamic acid exhibit antitumor activity alone and combined with carboplatin in platinum-resistant high-grade serous ovarian cancer models.

  2026cites this paper
• Discovery of highly potent AKR1Cs pan-inhibitors as chemotherapeutic potentiators to restore breast cancer drug resistance.

  2025cites this paper
• Exploring Strategies to Prevent and Treat Ovarian Cancer in Terms of Oxidative Stress and Antioxidants

  2025cites this paper
• Analysis of the mechanism of aldo-keto reductase dependent cis-platin resistance in HepG2 cells based on transcriptomic and NADH metabolic state

  2023cites this paper
• Insight into the Basic Mechanisms and Various Modulation Strategies Involved in Cancer Drug Resistance.

  2023cites this paper
• AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin

  2022cites this paper
• Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line

  2022cites this paper
• New Insight on Vitality Differences for the Penaeid Shrimp, Fenneropenaeus chinensis, in Low Salinity Environment Through Transcriptomics

  2022cites this paper
• AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer

  2022cites this paper
• Aldo-Keto Reductases and Cancer Drug Resistance

  2021cites this paper
• Aldo-Keto Reductases and Cancer Drug Resistance and Epigenetic Regulation of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 Pathway Mediated by Aldo-Keto of Nuclear Factor-Erythroid 2 p45-Related Factor 2 and AKR Inhibitors to Surmount

  2021cites this paper
• Aldo-Keto Reductases and Cancer Drug Resistance and Epigenetic Regulation of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 Pathway Mediated by Aldo-Keto of Nuclear Factor-Erythroid 2 p45-Related Factor 2 and AKR Inhibitors to Surmount

  2021cites this paper
• Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer

  2021cites this paper
• Bioinformatics analysis and verification of molecular targets in ovarian cancer stem-like cells

  2020cites this paper
• Pathway-centric generalizable computational framework uncovers pathway markers governing chemoresistance across cancers

  2020cites this paper
• Higher levels of dynamin-related protein 1 are associated with reduced radiation sensitivity of glioblastoma cells.

  2020cites this paper
• Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells

  2020cites this paper
• pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma

  2019cites this paper
• Reducing expression of dynamin-related protein 1 increases radiation sensitivity of glioblastoma cells

  2019cites this paper
• Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology

  2019cites this paper
• Genome-wide gene expression analysis reveals novel insights into the response to nitrite stress in gills of Branchiostoma belcheri.

  2019cites this paper
• AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

  2019cites this paper
• 2-Deoxy-D-glucose Mediates Dihydrodiol Dehydrogenases Over-expression and Cisplatin Resistance in Human Cervical Cancer Cells

  2019cites this paper
• The Aldo-Keto Reductase Superfamily

  2018cites this paper
• Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.

  2017cites this paper
• The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy

  2017cites this paper
• Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses

  2017cites this paper
• Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy

  2017cites this paper
• Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene

  2017cites this paper
• Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.

  2017cites this paper
• The miR‐200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR‐3 and MES‐OV cells

  2015cites this paper
• Cisplatin resistance in human cervical, ovarian and lung cancer cells

  2015cites this paper
• Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis

  2014cites this paper
• Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer.

  2014cites this paper
• Extracts of Koelreuteria henryi Dummer induce apoptosis and autophagy by inhibiting dihydrodiol dehydrogenase, thus enhancing anticancer effects.

  2013cites this paper
• Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.

  2013cites this paper
• Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.

  2013cites this paper
• Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.

  2013cites this paper
• Hepatitis B Virus X Protein Up-Regulates AKR1C1 Expression Through Nuclear Factor-Y in Human Hepatocarcinoma Cells

  2013cites this paper
• Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers.

  2013cites this paper
• MECHANISMS OF ANTICANCER DRUGS RESISTANCE: AN OVERVIEW

  2012cites this paper
• Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.

  2012cites this paper
• Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

  2012cites this paper
• LA-ICP-MS and nHPLC-ESI-LTQ-FT-MS/MS for the analysis of cisplatin–protein complexes separated by two dimensional gel electrophoresis in biological samples

  2012cites this paper
• Regulation of Aldo–Keto Reductases in Human Diseases

  2012cites this paper
• Original Article Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell car- cinoma but not small cell carcinoma

  2012cites this paper
• Aldo–Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers

  2011cites this paper
• Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

  2011cites this paper
• Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells.

  2011cites this paper
• Human papillomavirus infection and expression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer.

  2011cites this paper
• Human papillomavirus infection and expression of ATPase family AAA domain containing 3 A , a novel anti-autophagy factor , in uterine cervical cancer

  2011cites this paper
• Structure-activity screening of platinum intercalators and molecular mechanisms for the cytotoxicity of 56MESS - [Pt(5,6-Dimethyl-Phen)(1S,2S-DACH)]²⁺

  2011cites this paper
• An investigation into the regulation and expression of the tumour suppressor gene clusterin in oral, cervical and nasopharyngeal cancer

  2010cites this paper
• Aldo-Keto Reductases

  2010cites this paper
• Resistance to platinum-based chemotherapy in lung cancer cell lines

  2010cites this paper
• Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.

  2010cites this paper
• Overexpression of aldo‐keto reductase 1C2 is associated with disease progression in patients with prostatic cancer

  2010cites this paper
• The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.

  2010cites this paper
• Optic atrophy 1 increases cisplatin resistance via inhibition of caspase-dependent cell death

  2010cites this paper
• IDENTIFICACIÓ DELS NODES GENÒMICS DE RESPOSTA AL TRACTAMENT QUIMIOTERAPÈUTIC: TERÀPIA COMBINADA AMB siRNA.

  2009cites this paper
• Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker in Resected Gastric Cancer Patients

  2009cites this paper
• Genomics of Smoking Exposure and Cessation: Lessons for Cancer Prevention and Treatment

  2008cites this paper
• Cadmium, cobalt and lead cause stress response, cell cycle deregulation and increased steroid as well as xenobiotic metabolism in primary normal human bronchial epithelial cells which is coordinated by at least nine transcription factors

  2008cites this paper
• Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells

  2008cites this paper
• Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.

  2008cites this paper
• Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.

  2007cites this paper
• Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas

  2007cites this paper
• Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer.

  2007cites this paper
• Reversal of inflammation‐associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin

  2007cites this paper
• Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.

  2007cites this paper
• Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.

  2007cites this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cites this paper
• Aldo-keto reductases and bioactivation/detoxication.

  2007cites this paper
• Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer.

  2006cites this paper
• Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma.

  2006cites this paper
• Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin

  2006cites this paper
• Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2

  2006influential citation
• Induction of AKR 1 C 2 by Phase II Inducers : Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF 2

  2006influential citation
• Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1‐R10

  2006cites this paper
• Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung.

  2006cites this paper
• Genomic tests for ovarian cancer detection and management.

  2006cites this paper
• Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy

  2006cites this paper
• AKR1B10: A New Diagnostic Marker of Non–Small Cell Lung Carcinoma in Smokers

  2005cites this paper
• Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.

  2005cites this paper
• Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.

  2005cites this paper
• Gene profiling in muscle of severely burned children: age- and sex-dependent changes.

  2005cites this paper
• Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain

  2005cites this paper
• Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy

  2005cites this paper
• Mechanisms of Drug Resistance in Cancer Chemotherapy

  2005cites this paper
• Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.

  2005cites this paper
• Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

  2005cites this paper
• Impact of Smoking Cessation on Global Gene Expression in the Bronchial Epithelium of Chronic Smokers

  2005cites this paper
• Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.

  2005cites this paper
• Inverse expression of dihydrodiol dehydrogenase and glutathione‐S‐transferase in patients with esophageal squamous cell carcinoma

  2004cites this paper
• Differential gene expression between squamous cell carcinoma of esophageus and its normal epithelium; altered pattern of mal, akr1c2, and rab11a expression.

  2004cites this paper
• Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase

  2004cites this paper
• Role of the transcription factor Ets-1 in cisplatin resistance.

  2004cites this paper
• Cisplatin and related anticancer drugs: recent advances and insights.

  2004cites this paper
• Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells.

  2003cites this paper
• Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

  2003cites this paper